Mingxi Li is a Partner at GT Healthcare Capital Partners, an Asia-based venture capital firm specializing in global. See sector focus and contact routes.
Mingxi Li is a Partner at GT Healthcare Capital Partners, an Asia-based venture capital firm specializing in global healthcare investments, and also serves as CEO of Apeiron Therapeutics, a biotech company he co-founded to commercialize early-stage life science innovations. His investment thesis centers on early-stage life science and healthcare technologies, with a focus on cross-border opportunities between China and global markets, particularly in pharma, diagnostics, and biotechnology. While specific check sizes and lead/follow behavior are not publicly documented, Li has managed over $150 million in venture fund investments during his prior role as Senior Director at Simcere Pharmaceutical Group, indicating experience with substantial capital deployment. Notable portfolio connections include his leadership in investing in Zhejiang Chengyi Pharmaceutical (SH: 603811) at Jiuding Capital and his board roles at multiple prominent Chinese pharmaceutical and diagnostic companies. Li distinguishes himself as a “venturepreneur,” combining deep scientific expertise—holding a Ph.D. in Biochemistry from the University of Illinois—with hands-on entrepreneurial experie
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Jingan.
Investors like Mingxi Li · Full investor directory · Investor access · Company funding database